trending Market Intelligence /marketintelligence/en/news-insights/trending/PklnXCKGZJm5jBL7Ht-I1Q2 content esgSubNav
In This List

Horizon Pharma secures preliminary patent approval for urea disorder drug

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Horizon Pharma secures preliminary patent approval for urea disorder drug

Horizon Pharma PLC secured preliminary approval for a U.S. patent that would cover its Ravicti oral treatment for urea cycle disorders in patients older than two years of age.

The U.S. Patent and Trademark Office issued a notice of allowance for the patent that would expire on Sept. 22, 2030, once granted.